Q: Peter et al.
Any thoughts on this one. It is the rebranded Bioniche. They recently got an FDA notification that their bladder cancer drug (Urocidin) will get FDA fast-track review. They seem well cashed up, but do have a lot of shares outstanding (280 million). Thanks.
Any thoughts on this one. It is the rebranded Bioniche. They recently got an FDA notification that their bladder cancer drug (Urocidin) will get FDA fast-track review. They seem well cashed up, but do have a lot of shares outstanding (280 million). Thanks.